TNGX250117C5000
- 0.15
- 0.000.00%
Tango Therapeutics Newsroom
Express News | Cantor Fitzgerald Reiterates Overweight on Tango Therapeuticsto Overweight
Tango Therapeutics Analyst Ratings
Express News | Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Tango Therapeutics Granted FDA Orphan Designation Status For "Small Molecule Inhibitor of PRMT5 (Protein Arginine Methyl Transferase 5)" Treatment Of Pancreatic Cancer
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
Tango Therapeutics Inc. (TNGX): Among the Most Promising Cancer Stocks According to Hedge Funds
Versant Ventures Unveils Pep2Tango Therapeutics Inc.
Independent Director of Tango Therapeutics Mace Rothenberg Buys 400% More Shares
The Analyst Landscape: 5 Takes On Tango Therapeutics
B.Riley Financial Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Cuts Target Price to $8
Tango Therapeutics Price Target Lowered to $8 From $16 at B. Riley
Tango Therapeutics(TNGX.US) 10% Shareholder Sells US$8.44 Million in Common Stock
Guggenheim Initiates Tango Therapeutics(TNGX.US) With Buy Rating, Announces Target Price $8
H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $13
Promising Developments and Strategic Shifts at Tango Therapeutics: A Buy Rating With a $13 Price Target
Tango Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Positive Outlook for Tango Therapeutics: Promising TNG462 Data and Strategic Focus
Tango Therapeutics(TNGX.US) Insider Sells US$9.67 Million in Common Stock
Tango Therapeutics Is Maintained at Buy by Guggenheim